Cliff Asness's TGTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 442,287 shares of TG Therapeutics, Inc. (TGTX) worth $24.3 M, representing 0.01% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in TGTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2026, adding 208,181 shares. Largest reduction occurred in Q4 2015, reducing 53,123 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +98,098 | Add 28.50% | 442,287 | $54.94 |
| Q1 2026 | +208,181 | Add 153.07% | 344,189 | $33.22 |
| Q4 2025 | +68,197 | Add 100.57% | 136,008 | $29.81 |
| Q3 2025 | +34,462 | Add 103.34% | 67,811 | $36.13 |
| Q2 2025 | -1,944 | Reduce 5.51% | 33,349 | $35.99 |
| Q1 2025 | -32,574 | Reduce 48.00% | 35,293 | $39.43 |
| Q4 2024 | +8,431 | Add 14.19% | 67,867 | $30.10 |
| Q3 2024 | +21,411 | Add 56.31% | 59,436 | $23.39 |
| Q2 2024 | -6,339 | Reduce 14.29% | 38,025 | $17.79 |
| Q1 2024 | +26,477 | Add 148.02% | 44,364 | $15.21 |
| Q4 2023 | -41,968 | Reduce 70.12% | 17,887 | $17.08 |
| Q3 2023 | -3,783 | Reduce 5.94% | 59,855 | $8.36 |
| Q2 2023 | +20,261 | Add 46.71% | 63,638 | $24.84 |
| Q1 2023 | +43,377 | New Buy | 43,377 | $15.04 |
| Q2 2022 | -34,081 | Sold Out | 0 | $0.00 |
| Q4 2021 | -16,354 | Reduce 32.43% | 34,081 | $19.01 |
| Q3 2021 | -12,173 | Reduce 19.44% | 50,435 | $33.27 |
| Q1 2021 | -9,148 | Reduce 12.75% | 62,608 | $48.20 |
| Q4 2020 | -5,012 | Reduce 6.53% | 71,756 | $52.02 |
| Q3 2020 | +7,898 | Add 11.47% | 76,768 | $26.76 |
| Q2 2020 | +24,075 | Add 53.74% | 68,870 | $19.49 |
| Q1 2020 | +8,624 | Add 23.84% | 44,795 | $9.84 |
| Q4 2019 | +36,171 | New Buy | 36,171 | $11.09 |
| Q4 2018 | -16,948 | Sold Out | 0 | $0.00 |
| Q3 2018 | -18,836 | Reduce 52.64% | 16,948 | $5.61 |
| Q2 2018 | -11,483 | Reduce 24.29% | 35,784 | $13.16 |
| Q1 2018 | +730 | Add 1.57% | 47,267 | $14.20 |
| Q3 2017 | +36,263 | Add 352.96% | 46,537 | $11.84 |
| Q2 2017 | +10,274 | New Buy | 10,274 | $10.03 |
| Q4 2015 | -53,123 | Sold Out | 0 | $0.00 |
| Q3 2015 | -9,937 | Reduce 15.76% | 53,123 | $10.07 |
| Q2 2015 | +13,560 | Add 27.39% | 63,060 | $16.59 |
| Q1 2015 | +1,100 | Add 2.27% | 49,500 | $15.47 |
| Q4 2014 | +19,500 | Add 67.47% | 48,400 | $15.85 |
| Q3 2014 | +11,400 | Add 65.14% | 28,900 | $10.66 |
| Q2 2014 | -25,600 | Reduce 59.40% | 17,500 | $9.37 |
| Q4 2013 | +32,900 | Add 322.55% | 43,100 | $3.90 |
| Q3 2013 | +10,200 | New Buy | 10,200 | $5.10 |
Cliff Asness's TG Therapeutics Investment FAQs
Cliff Asness first purchased TG Therapeutics, Inc. (TGTX) in Q3 2013, acquiring 10,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held TG Therapeutics, Inc. (TGTX) for 42 quarters since Q3 2013.
Cliff Asness's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2026, adding 344,189 shares worth $11.43 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 442,287 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $24.3 M.
As of the Q2 2026 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in TG Therapeutics, Inc. (TGTX) was 442,287 shares, as reported at the end of Q2 2026.